Jeffrey Bluestone Healthcare News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected healthcare news for Jeffrey Bluestone, which is filed under People. There are 19 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
4/13/2022 Versant-backed startup launches with plans to broaden cell therapy's reach
... least some of these problems can be overcome. Called Cimeio Therapeutics , the new company is led by a team of pharmaceutical industry veterans and an advisory board filled with scientific luminaries, including immunologist Jeffrey Bluestone and gene editing pioneer Fyodor Urnov. Cimeio's approach involves "shielding" transplanted cells by genetically editing ...
BioPharma Dive
9/16/2021 Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary
... team to help guide the strategic business decisions of the company. “We are delighted to welcome Doug to the team as we continue this period of rapid growth as a company,” said Jeffrey Bluestone, Ph.D., Co-founder and CEO of Sonoma Biotherapeutics. “His decades of biopharma legal experience will ...
Business Wire
8/4/2021 Sonoma Bio bags $265M to rev up cell therapies for arthritis, diabetes
... for autoimmune diseases, including Type 1 diabetes and rheumatoid arthritis. Its cell therapies are based on regulatory T cells, or Tregs, which identify unwanted inflammatory and autoimmune responses and shut them down, said Jeffrey Bluestone, Ph.D., CEO and co-founder of Sonoma Bio. Since its launch, the company has added ...
FierceBiotech
2/6/2020 Sonoma Bio debuts with $40M to push Treg treatments for autoimmune, neuro diseases FierceBiotech
2/6/2020 Sonoma Biotherapeutics Launches With $40 Million In Series A Funding To Advance Regulatory T Cell Therapy In Autoimmune And Degenerative Diseases - TheStreet TheStreet
2/6/2020 Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases STAT
1/14/2020 Opinion: Innovation in biotech R&D: New resources offer new hope STAT
5/10/2019 The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research ascopost.com
5/10/2019 How the Nobel Prize Could Spur More Cancer Advances ascopost.com
5/10/2019 Advancing Immune Checkpoint Targeting in Cancer Treatment ascopost.com
10/31/2017 BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials of Treg Cell Therapies PR Newswire
10/31/2017 BioLife Solutions and SAVSU Providing Enhanced Cold Chain Technologies for 8 UCSF Clinical Trials PR Newswire